Who are Cipro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zymar, Avelox, Cipro, Experimental: Active "I-Reconstruction" Therapy, levofloxacin-based triple therapy, Moxifloxacin Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ciprofloxacin-in-dextrose-5-in-plastic-container.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cipro — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cipro (Ciprofloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone.

marketed Fluoroquinolone DNA gyrase Small molecule Live · refreshed every 30 min

Target snapshot

Cipro (Ciprofloxacin) — Alk Abello. Ciprofloxacin interferes with bacterial DNA gyrase, inhibiting DNA synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cipro TARGET	Ciprofloxacin	Alk Abello	marketed	Fluoroquinolone	DNA gyrase	1987-01-01
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Avelox	moxifloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Experimental: Active "I-Reconstruction" Therapy	Experimental: Active "I-Reconstruction" Therapy	International Association Psychosomatics And Health Therapy	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
levofloxacin-based triple therapy	levofloxacin-based triple therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (in combination therapy)	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin Injectable Product	Moxifloxacin Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Fluoroquinolone class)

Alk Abello · 1 drug in this class
Innovative Medical · 1 drug in this class
International Association Psychosomatics And Health Therapy · 1 drug in this class
National University of Malaysia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cipro — Competitive Intelligence Brief. https://druglandscape.com/ci/ciprofloxacin-in-dextrose-5-in-plastic-container. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab